Beddow Capital Management Inc. Raises Stock Position in Organon & Co. (NYSE:OGN)

Beddow Capital Management Inc. raised its position in Organon & Co. (NYSE:OGN) by 38.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 306,675 shares of the company’s stock after purchasing an additional 85,775 shares during the period. Organon & Co. accounts for 2.4% of Beddow Capital Management Inc.’s investment portfolio, making the stock its 18th biggest position. Beddow Capital Management Inc. owned about 0.12% of Organon & Co. worth $5,867,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. Mercer Global Advisors Inc. ADV boosted its stake in Organon & Co. by 1.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock worth $674,000 after buying an additional 546 shares in the last quarter. Ballentine Partners LLC raised its position in Organon & Co. by 3.0% in the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock worth $395,000 after purchasing an additional 552 shares during the period. Bill Few Associates Inc. lifted its stake in Organon & Co. by 5.4% in the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock worth $253,000 after purchasing an additional 621 shares during the last quarter. Sippican Capital Advisors boosted its position in Organon & Co. by 4.3% during the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock valued at $291,000 after buying an additional 627 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of Organon & Co. by 19.2% in the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after acquiring an additional 649 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OGN has been the topic of several research analyst reports. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and boosted their price target for the company from $18.00 to $20.00 in a research report on Friday, September 6th. Evercore ISI upgraded Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Trading Up 0.5 %

Shares of OGN stock opened at $15.11 on Tuesday. The company has a market cap of $3.89 billion, a price-to-earnings ratio of 3.00, a PEG ratio of 0.70 and a beta of 0.84. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The firm has a fifty day moving average price of $18.04 and a 200-day moving average price of $19.92. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the business earned $0.78 EPS. As a group, equities analysts predict that Organon & Co. will post 3.89 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Tuesday, November 12th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a yield of 7.41%. The ex-dividend date is Tuesday, November 12th. Organon & Co.’s dividend payout ratio is currently 22.22%.

Organon & Co. Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.